<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01479439</url>
  </required_header>
  <id_info>
    <org_study_id>2010-3070</org_study_id>
    <nct_id>NCT01479439</nct_id>
  </id_info>
  <brief_title>Losartan to Reverse Sickle Nephropathy</brief_title>
  <official_title>A Phase II Trial of Losartan to Reverse Sickle Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sickle cell disease causes kidney damage with increasing age, leading to chronic kidney&#xD;
      disease and renal failure in nearly one third of patients with sickle cell disease.&#xD;
      Currently, there is no treatment for sickle cell related kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to see if losartan can help reduce or reverse damage&#xD;
      done to the kidneys of children and adults with Sickle Cell Anemia (SCA) and Sickle Beta-zero&#xD;
      (HbSβ0) Thalassemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Categorical Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Number of participants who have a ≥25% reduction in urinary albumin-to-creatinine ratio (UACR) from baseline to 6 months. This is a categorical outcome (yes/no).&#xD;
We hypothesized and pre-specified that ≥30% of the subjects in the microalbuminuria group would meet this outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in UACR</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Fold-change in UACR from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Creatinine Clearance</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Fold-change in creatinine clearance by 24h urine collection (GFR-CrCl) from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Nephropathy</condition>
  <condition>Sickle Cell Anemia</condition>
  <arm_group>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The purpose of this research study is to see if losartan can help reduce or reverse damage done to the kidneys of children and adults with Sickle Cell Anemia (SCA) and Sickle Beta-zero (HbSβ0) Thalassemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Form: suspension, tablet. Dosage &amp; frequency: age 6-16 = 0.7mg/kg once daily; age &gt;16 = 50mg once daily. Duration: 6 months</description>
    <arm_group_label>Sickle cell disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥6 years of age; for no albuminuria (NoA) group age is ≥ 6 years and &lt;21 years of&#xD;
             age&#xD;
&#xD;
          2. Diagnosis of hemoglobin SS disease or Sβ0 thalassemia by hemoglobin electrophoresis&#xD;
             and/or β-globin gene mapping.&#xD;
&#xD;
          3. Urine osmolality &lt;700 mOsm (milliosmoles) on first morning urine&#xD;
&#xD;
          4. Written informed consent (and assent, where applicable)&#xD;
&#xD;
          5. Documented urine albumin to creatinine ratio (UACR) showing either&#xD;
&#xD;
               -  NoA: UACR &lt;30mg/g creatinine on a first morning urine&#xD;
&#xD;
               -  MiA: UACR 30-300 mg/g creatinine on a first morning urine or&#xD;
&#xD;
               -  MaA: UACR &gt;300 mg/g creatinine on a first morning urine sample&#xD;
&#xD;
          6. A documented negative serum pregnancy test for females with child bearing potential or&#xD;
             greater than 10 years of age within (prior to) 7 days of starting the study&#xD;
             medication.&#xD;
&#xD;
          7. Subjects with child-bearing potential must be willing to use a medically accepted form&#xD;
             of contraception throughout the study.&#xD;
&#xD;
          8. Patients on hydroxyurea (HU) who are on a stable (not changing) dose of HU for three&#xD;
             months prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with Hb SC, SD, Sβ+thal, SE and other sickle hemoglobinopathies, and sickle&#xD;
             trait (AS).&#xD;
&#xD;
          2. Pregnant or lactating females, or females of child-bearing potential that are unable&#xD;
             to use a medically accepted form of contraception throughout the study.&#xD;
&#xD;
          3. Urine creatinine clearance (Clcr) &lt;60 mL/minute/1.73 m2&#xD;
&#xD;
          4. Gross (not microscopic) hematuria. If hematuria has resolved for 2 weeks or more,&#xD;
             patients will be eligible.&#xD;
&#xD;
          5. Hyperkalemia (K≥5.5) at baseline despite a low potassium diet&#xD;
&#xD;
          6. Concurrent condition that predisposes to nephropathy, such as lupus, diabetes, and&#xD;
             hypertension, not controlled with medications..&#xD;
&#xD;
          7. On a renin-angiotensin pathway inhibitor (e.g., captopril, lisinopril, Losartan,&#xD;
             valsartan, etc) for the last two weeks prior to enrollment.&#xD;
&#xD;
          8. Hypersensitivity to Angiotensin II receptor blockers such as losartan, valsartan,&#xD;
             telmisartan.&#xD;
&#xD;
          9. Patients on red cell apheresis or ongoing aggressive chronic transfusions (one or more&#xD;
             a month with a goal of HbS &lt; 30%). Patients receiving a simple transfusion for&#xD;
             symptoms during acute event will be eligible, but if they receive a partial or full&#xD;
             exchange transfusion during an acute event, then they will only be eligible after 90&#xD;
             days.&#xD;
&#xD;
         10. Hepatic dysfunction defined as ALT (alanine aminotransferase) or direct bilirubin &gt;&#xD;
             3-times upper limit of normal (ULN).&#xD;
&#xD;
         11. Chronic therapy with NSAIDS or Cox2 inhibitors&#xD;
&#xD;
         12. On another interventional trial. May be eligible two weeks after completion of another&#xD;
             interventional study.&#xD;
&#xD;
         13. Any condition that interferes with the ability of the patient to understand or comply&#xD;
             with the treatment plan and follow up.&#xD;
&#xD;
         14. A serious mental or physical illness or a major disease (cardiac, renal, hepatic,&#xD;
             neurological, endocrine, metabolic, pulmonary function or psychiatric), which in the&#xD;
             opinion of the investigator would compromise participation in the study.&#xD;
&#xD;
         15. Unable to take oral medications.&#xD;
&#xD;
         16. HIV confirmed positive.&#xD;
&#xD;
         17. Chronic therapy with steroids. May be eligible after three weeks of completing steroid&#xD;
             therapy.&#xD;
&#xD;
         18. Patients on lithium will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Punam Malik, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHLBI</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.24810</url>
    <description>Journal Site</description>
  </link>
  <results_reference>
    <citation>Quinn CT, Saraf SL, Gordeuk VR, Fitzhugh CD, Creary SE, Bodas P, George A, Raj AB, Nero AC, Terrell CE, McCord L, Lane A, Ackerman HC, Yang Y, Niss O, Taylor MD, Devarajan P, Malik P. Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. Am J Hematol. 2017 Sep;92(9):E520-E528. doi: 10.1002/ajh.24810. Epub 2017 Jul 19.</citation>
    <PMID>28589652</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 16, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2011</study_first_posted>
  <results_first_submitted>August 17, 2020</results_first_submitted>
  <results_first_submitted_qc>September 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2020</results_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a multicenter, phase 2, open-label study of losartan for sickle cell nephropathy. Participants were enrolled at nine centers in the United States between 2012 and 2015.</recruitment_details>
      <pre_assignment_details>Concomitant treatment with hydroxyurea was allowed, but the dose must have been stable in the 3 months preceding enrollment. Participants were allocated to three pre-specified groups defined by baseline urinary albumin-to-creatinine ratio (UACR).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Losartan - No Albuminuria</title>
          <description>Baseline urinary albumin-to-creatinine ratio (UACR) &lt;30 mg/g.&#xD;
All participants in this study in all arms were treated with losartan using the same dosing regimen. Study arms are only differentiated by baseline UACR.</description>
        </group>
        <group group_id="P2">
          <title>Losartan - Microalbuminuria</title>
          <description>Baseline urinary albumin-to-creatinine ratio (UACR) 30-300 mg/g.&#xD;
All participants in this study in all arms were treated with losartan using the same dosing regimen. Study arms are only differentiated by baseline UACR.</description>
        </group>
        <group group_id="P3">
          <title>Losartan - Macroalbuminuria</title>
          <description>Baseline urinary albumin-to-creatinine ratio (UACR) &gt;300 mg/g.&#xD;
All participants in this study in all arms were treated with losartan using the same dosing regimen. Study arms are only differentiated by baseline UACR.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Losartan - No Albuminuria</title>
          <description>Baseline urinary albumin-to-creatinine ratio (UACR) &lt;30 mg/g.&#xD;
All participants in this study in all arms were treated with losartan using the same dosing regimen. Study arms are only differentiated by baseline UACR.</description>
        </group>
        <group group_id="B2">
          <title>Losartan - Microalbuminuria</title>
          <description>Baseline urinary albumin-to-creatinine ratio (UACR) 30-300 mg/g.&#xD;
All participants in this study in all arms were treated with losartan using the same dosing regimen. Study arms are only differentiated by baseline UACR.</description>
        </group>
        <group group_id="B3">
          <title>Losartan - Macroalbuminuria</title>
          <description>Baseline urinary albumin-to-creatinine ratio (UACR) &gt;300 mg/g.&#xD;
All participants in this study in all arms were treated with losartan using the same dosing regimen. Study arms are only differentiated by baseline UACR.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6" spread="4.9"/>
                    <measurement group_id="B2" value="28.6" spread="16.6"/>
                    <measurement group_id="B3" value="38.8" spread="18.5"/>
                    <measurement group_id="B4" value="24.4" spread="88.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary albumin-to-creatinine ratio (UACR) (mg/g)</title>
          <description>The ratio of urinary albumin concentration (in mg) to urinary creatinine concentration (in g).</description>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" spread="4.9"/>
                    <measurement group_id="B2" value="121" spread="86.6"/>
                    <measurement group_id="B3" value="815" spread="335.6"/>
                    <measurement group_id="B4" value="202" spread="333.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine clearance by 24h Urine Collection</title>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146" spread="228"/>
                    <measurement group_id="B2" value="172" spread="204"/>
                    <measurement group_id="B3" value="108" spread="46.5"/>
                    <measurement group_id="B4" value="150" spread="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Categorical Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline</title>
        <description>Number of participants who have a ≥25% reduction in urinary albumin-to-creatinine ratio (UACR) from baseline to 6 months. This is a categorical outcome (yes/no).&#xD;
We hypothesized and pre-specified that ≥30% of the subjects in the microalbuminuria group would meet this outcome.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan - No Albuminuria</title>
            <description>Baseline urinary albumin-to-creatinine ratio (UACR) &lt;30 mg/g.&#xD;
All participants in this study in all arms were treated with losartan using the same dosing regimen. Study arms are only differentiated by baseline UACR.</description>
          </group>
          <group group_id="O2">
            <title>Losartan - Microalbuminuria</title>
            <description>Baseline urinary albumin-to-creatinine ratio (UACR) 30-300 mg/g.&#xD;
All participants in this study in all arms were treated with losartan using the same dosing regimen. Study arms are only differentiated by baseline UACR.</description>
          </group>
          <group group_id="O3">
            <title>Losartan - Macroalbuminuria</title>
            <description>Baseline urinary albumin-to-creatinine ratio (UACR) &gt;300 mg/g.&#xD;
All participants in this study in all arms were treated with losartan using the same dosing regimen. Study arms are only differentiated by baseline UACR.</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline</title>
          <description>Number of participants who have a ≥25% reduction in urinary albumin-to-creatinine ratio (UACR) from baseline to 6 months. This is a categorical outcome (yes/no).&#xD;
We hypothesized and pre-specified that ≥30% of the subjects in the microalbuminuria group would meet this outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in UACR</title>
        <description>Fold-change in UACR from baseline</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Albuminuria (NoA)</title>
            <description>Baseline urinary albumin-to-creatinine ratio (UACR) &lt;30 mg/g</description>
          </group>
          <group group_id="O2">
            <title>Microalbuminuria (MicroA)</title>
            <description>Baseline urinary albumin-to-creatinine ratio (UACR) 30-300 mg/g</description>
          </group>
          <group group_id="O3">
            <title>Macroalbuminuria</title>
            <description>Baseline urinary albumin-to-creatinine ratio (UACR) &gt;300 mg/g</description>
          </group>
        </group_list>
        <measure>
          <title>Change in UACR</title>
          <description>Fold-change in UACR from baseline</description>
          <units>Fold-change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="-0.07" upper_limit="1.06"/>
                    <measurement group_id="O2" value="-0.46" lower_limit="-0.75" upper_limit="2.53"/>
                    <measurement group_id="O3" value="-0.74" lower_limit="-0.91" upper_limit="-0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Creatinine Clearance</title>
        <description>Fold-change in creatinine clearance by 24h urine collection (GFR-CrCl) from baseline</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Albuminuria (NoA)</title>
            <description>Baseline urinary albumin-to-creatinine ratio (UACR) &lt;30 mg/g</description>
          </group>
          <group group_id="O2">
            <title>Microalbuminuria (MicroA)</title>
            <description>Baseline urinary albumin-to-creatinine ratio (UACR) 30-300 mg/g</description>
          </group>
          <group group_id="O3">
            <title>Macroalbuminuria</title>
            <description>Baseline urinary albumin-to-creatinine ratio (UACR) &gt;300 mg/g</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Creatinine Clearance</title>
          <description>Fold-change in creatinine clearance by 24h urine collection (GFR-CrCl) from baseline</description>
          <units>Fold-change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="-0.10" upper_limit="0.44"/>
                    <measurement group_id="O2" value="0.12" lower_limit="-0.34" upper_limit="0.26"/>
                    <measurement group_id="O3" value="0.05" lower_limit="-0.01" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>No Albuminuria (NoA)</title>
          <description>Baseline urinary albumin-to-creatinine ratio (UACR) &lt;30 mg/g</description>
        </group>
        <group group_id="E2">
          <title>Microalbuminuria (MicroA)</title>
          <description>Baseline urinary albumin-to-creatinine ratio (UACR) 30-300 mg/g</description>
        </group>
        <group group_id="E3">
          <title>Macroalbuminuria</title>
          <description>Baseline urinary albumin-to-creatinine ratio (UACR) &gt;300 mg/g</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Cramps</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in serum creatinine &gt;50% from baseline</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Decline in GFR &gt;25% from baseline</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We cannot conclude from this small phase 2 study that losartan is efficacious for sickle cell nephropathy. Rather, the data generated from this study will inform the design of a phase-3 randomized trial to determine its efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Charles Quinn</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>5138033086</phone>
      <email>charles.quinn@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

